- Company
- Somavert can be prescribed at general hospitals
- by Eo, Yun-Ho Nov 16, 2021 05:52am
- According to related industries, Pfizer Korea's Somavert (Pegvisomant) has currently passed the Drug Committee (DC) of medical institutions such as Seoul National University Hospital and Sinchon Severance Hospital, and is also undergoing procedures at medical institutions such as Seoul National University Bundang Hospital, Wonju Severance Ho
- Company
- Sales of Arcoxia (Etoricoxib) are sluggish
- by Kim, Jin-Gu Nov 16, 2021 05:52am
- Generics for Arcoxia, an anti-inflammatory pain reliever based on COX-2 inhibitors (Etoricoxib) have been released, but sales in the market are sluggish. This is because there is still a high preference for original drugs at the medical site, and even the original drugs are pushed back by Celebrex, a leading item in the same family market.
- Company
- The price reduction of PE waiver drugs
- by Eo, Yun-Ho Nov 15, 2021 06:29pm
- KRPIA expressed serious concern in a comment on the 10th that the HIRA was confirmed to evaluate the cost effectiveness at 80% of the lowest A7 adjustment price when asked about the cost-effectiveness criteria of Kim Mi-ae, a member of the National Assembly. KRPIA said, "In the course of discussions with the HIRA, we have repeatedly expressed
- Company
- Will sales of flu treatments be recovered?
- by Chon, Seung-Hyun Nov 15, 2021 05:56pm
- According to UBIST, a drug research institute, on the 14th, the amount of outpatient prescriptions for flu treatments in the third quarter was only 7.97 million won. It fell 31.1% year-on-year. It decreased by 75.2% from the same period two years ago. The flu treatment market has been prescribing less than 100 million won for six consecutive
- Opinion
- [Reporter’s View] On HIRA's price cuts for PE waiver drugs
- by Eo, Yun-Ho Nov 15, 2021 05:56am
- HIRA’s unilateral notice of its decision leaves a lingering question on whether this really was the best way to conclude the discussions. Couldn't the government have included its favorite words - "in discussion" or "in coordination" - that it uses best? The Health Insurance Review and Assessment Service responded that the criteria for e
- Company
- K-COVID-19 vaccine developers will ‘power through till end'
- by Kim, Jin-Gu Nov 15, 2021 05:56am
- Domestic vaccine developers have been accelerating the last phases of their clinical trials. SK Bioscience and Genexine have started Phase III trials in Korea and abroad, and Cellid has submitted its Phase IIb/III clinical trial plan. Domestic developers have come up with new strategies to continue the development of their vaccines with t
- Policy
- Rx drugs,allowed according to CTD starting from next year
- by Lee, Tak-Sun Nov 15, 2021 05:56am
- The MFDS announced on the 11th that it will partially revise the Regulation on Drug Product Authorization, Declaration, & Review to secure the quality reliability of generics in accordance with international standards. The revision includes improving the management of manufacturing methods such as Rx drugs manufacturing processes, deleting
- Company
- Keytruda reimb. not deliberated in November PBAC meeting
- by Eo, Yun-Ho Nov 12, 2021 10:23am
- Whether the reimbursement extension for ‘Keytruda’ may be completed by the end of this year remains in question. According to industry sources, MSD Korea’s PD-1 inhibitor Keytruda (pembrolizumab) was not put on the agenda for deliberation by the Health Insurance Review and Assessment Service’s Pharmaceutical Benefit Appraisal Committ
- Company
- Hanmi Pharmaceutical's first technology export in a year
- by Chon, Seung-Hyun Nov 12, 2021 05:56am
- Hanmi Pharmaceutical is speeding up its efforts to secure profits from technology fees, which had slowed down for a while. It has secured a down payment of 10 billion won by exporting new drug technology in the past year, and expectations are high for subsequent new drug development. According to an industry on the 11th, Hanmi Pharmaceutical
- Policy
- More convenient new dementia treatments introduced to market
- by Lee, Tak-Sun Nov 12, 2021 05:54am
- With a series of new dementia treatments being approved in Korea, whether the market dominated by Aricept will falter is gaining attention. Aricept (donepezil hydrochloride, Eisai Korea) has been dominated the market with an 80% share in the Korean prescription market. The Ministry of Food and Safety approved Lundbeck Korea’s ‘Ebixa tab
